RT Journal Article
T1 Autoantibodies against type I IFNs in patients with critical influenza pneumonia.
A1 Zhang, Qian
A1 Pizzorno, Andrés
A1 Miorin, Lisa
A1 Bastard, Paul
A1 Gervais, Adrian
A1 Le Voyer, Tom
A1 Bizien, Lucy
A1 Manry, Jeremy
A1 Rosain, Jeremie
A1 Philippot, Quentin
A1 Goavec, Kelian
A1 Padey, Blandine
A1 Cupic, Anastasija
A1 Laurent, Emilie
A1 Saker, Kahina
A1 Vanker, Martti
A1 Särekannu, Karita
A1 Constances Cohort, 
A1 Garcia-Salum, Tamara
A1 Ferres, Marcela
A1 Le Corre, Nicole
A1 Sanchez-Cespedes, Javier
A1 Balsera-Manzanero, María
A1 Carratala, Jordi
A1 Retamar-Gentil, Pilar
A1 Abelenda-Alonso, Gabriela
A1 Valiente, Adoracion
A1 Tiberghien, Pierre
A1 Zins, Marie
A1 Debette, Stephanie
A1 Meyts, Isabelle
A1 Haerynck, Filomeen
A1 Castagnoli, Riccardo
A1 Notarangelo, Luigi D
A1 Gonzalez-Granado, Luis I
A1 Dominguez-Pinilla, Nerea
A1 Andreakos, Evangelos
A1 Triantafyllia, Vasiliki
A1 Rodriguez-Gallego, Carlos
A1 Sole-Violan, Jordi
A1 Ruiz-Hernandez, Jose Juan
A1 Rodriguez de Castro, Felipe
A1 Ferreres, Jose
A1 Briones, Marisa
A1 Wauters, Joost
A1 Vanderbeke, Lore
A1 Feys, Simon
A1 Kuo, Chen-Yen
A1 Lei, Wei-Te
A1 Ku, Cheng-Lung
A1 Tal, Galit
A1 Etzioni, Amos
A1 Hanna, Suhair
A1 Fournet, Thomas
A1 Casalegno, Jean-Sebastien
A1 Queromes, Gregory
A1 Argaud, Laurent
A1 Javouhey, Etienne
A1 Rosa-Calatrava, Manuel
A1 Cordero, Elisa
A1 Aydillo, Teresa
A1 Medina, Rafael A
A1 Kisand, Kai
A1 Puel, Anne
A1 Jouanguy, Emmanuelle
A1 Abel, Laurent
A1 Cobat, Aurélie
A1 Trouillet-Assant, Sophie
A1 Garcia-Sastre, Adolfo
A1 Casanova, Jean-Laurent
K1 Influenza A virus
K1 A549 Cells
K1 Prevalence
K1 Influenza Vaccines
K1 Virus Replication
AB Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10-5), especially those
PB Rockefeller University Press
YR 2022
FD 2022-09-16
LK http://hdl.handle.net/10668/19700
UL http://hdl.handle.net/10668/19700
LA en
NO Zhang Q, Pizzorno A, Miorin L, Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J Exp Med. 2022 Nov 7;219(11):e20220514.
DS RISalud
RD Apr 8, 2025